133 related articles for article (PubMed ID: 7641199)
1. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.
Kemp JD; Cardillo T; Stewart BC; Kehrberg E; Weiner G; Hedlund B; Naumann PW
Cancer Res; 1995 Sep; 55(17):3817-24. PubMed ID: 7641199
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity.
Kemp JD; Thorson JA; Stewart BC; Naumann PW
Cancer Res; 1992 Aug; 52(15):4144-8. PubMed ID: 1638529
[TBL] [Abstract][Full Text] [Related]
3. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.
White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS
Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor.
Kemp JD; Smith KM; Kanner LJ; Gomez F; Thorson JA; Naumann PW
Blood; 1990 Sep; 76(5):991-5. PubMed ID: 2393721
[TBL] [Abstract][Full Text] [Related]
5. The long-acting parenteral iron chelator, hydroxyethyl starch-deferoxamine, fails to protect against alcohol-induced liver injury in rats.
Sadrzadeh SM; Hallaway PE; Nanji AA
J Pharmacol Exp Ther; 1997 Feb; 280(2):1038-42. PubMed ID: 9023321
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats.
Roza AM; Slakey DP; Pieper GM; Van Ye TM; Moore-Hilton G; Komorowski RA; Johnson CP; Hedlund BE; Adams MB
J Lab Clin Med; 1994 Apr; 123(4):556-60. PubMed ID: 7511676
[TBL] [Abstract][Full Text] [Related]
7. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.
Sauvage CA; Mendelsohn JC; Lesley JF; Trowbridge IS
Cancer Res; 1987 Feb; 47(3):747-53. PubMed ID: 3802079
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
Brodie C; Siriwardana G; Lucas J; Schleicher R; Terada N; Szepesi A; Gelfand E; Seligman P
Cancer Res; 1993 Sep; 53(17):3968-75. PubMed ID: 8358725
[TBL] [Abstract][Full Text] [Related]
9. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion.
Gehlbach P; Purple RL
Invest Ophthalmol Vis Sci; 1994 Feb; 35(2):669-76. PubMed ID: 7509327
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
12. Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells.
Kemp JD; Smith KM; Mayer JM; Gomez F; Thorson JA; Naumann PW
Pathobiology; 1992; 60(1):27-32. PubMed ID: 1543548
[TBL] [Abstract][Full Text] [Related]
13. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of hydroxyethyl starch-deferoxamine in early sepsis.
Moch D; Schröppel B; Schoenberg MH; Schulz HJ; Thorab FC; Marzinzag M; Hedlund BE; Brückner UB
Shock; 1995 Dec; 4(6):425-32. PubMed ID: 8608400
[TBL] [Abstract][Full Text] [Related]
15. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor.
Kemp JD
Histol Histopathol; 1997 Jan; 12(1):291-6. PubMed ID: 9046063
[TBL] [Abstract][Full Text] [Related]
16. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
Amoroso AR; Clark JI; Litwin S; Hsieh-Ma S; Shi T; Alpaugh RK; Adams GP; Wolf EJ; Ring DB; Weiner LM
Cancer Res; 1996 Jan; 56(1):113-20. PubMed ID: 8548750
[TBL] [Abstract][Full Text] [Related]
17. Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells.
Taetle R; Honeysett JM
Cancer Res; 1987 Apr; 47(8):2040-4. PubMed ID: 3828993
[TBL] [Abstract][Full Text] [Related]
18. Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Kovar J; Naumann PW; Stewart BC; Kemp JD
Pathobiology; 1995; 63(2):65-70. PubMed ID: 8554701
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
